iRhythm Q2 revenue $102.1M (+26% YoY), raises FY22 guidance to $415-420M, loss widens

iRhythm Holdings, Inc.

2022-Q2 EPS reported -$2.51 revenue$194,429,000

Revenue $102.1M (+25.6% YoY); gross margin 68.8% (up 0.8pp).
Net loss $23.9M ($0.80 loss per share) vs $17.4M loss in Q2 2021.
FY22 revenue guidance raised to $415-420M (29-30% growth); adj. EBITDA loss guidance $(12.5)-$(17.5)M.
Cash $204.5M; record new account openings (+22% QoQ) and sequential revenue volume growth of 10%.
FDA 510(k) cleared Zio Watch (Verily partnership); CMS proposed reimbursement for Zio XT CPT codes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.